ESULTS DLINES
ublished over the weekend. The study’s primary endpoint was to prove that Lutathera in ide prolonged progression-free survival (PFS) in GEP-NET patients with well-differentiated, ults included meeting the primary endpoint with an extended median progression-free survival ra and octreotide LAR arm compared to 8.5 months with high-dose octreotide LAR alone. Data uding overall survival and long-term safety data continues. g Lutathera as a first-line molecular radiotherapy with long-acting octreotide in patients with ms. It strengthens evidence for the use of molecular radiotherapy earlier in the treatment pathway ll as supporting use in well-differentiated G3 NENs.” ist at Imperial College Healthcare NHS Trust London, UK
Made with FlippingBook flipbook maker